In a recent issue of the Clinical Journal of the American Society of Nephrology, Wu and colleagues reported on the predictive value of routine D-dimer measurements for future thromboembolic events ...

Merck KGaA’s protracted pursuit of SpringWorks Therapeutics may be nearing its endgame. The German drugmaker confirmed (PDF) it is in late-stage talks about buying the rare cancer biopharma for ...

The small molecules in question are ASTX029, an ERK1/2 inhibitor that has completed a phase 2 study, and ASTX295 an MDM2 antagonist that has undergone a phase 1 trial. Both candidates have ...

Department of Regulatory Bioorganic Chemistry, The Institute of Scientific and Industrial Research (SANKEN), Osaka University, 8-1 Mihogaoka, Osaka, Ibaraki 567-0047, Japan Institute for Protein ...

None of the cases exhibited positive IgG4 plasma cells or MDM2 amplification. Table 1. Clinicopathologic features of all reported cases of the perinephric myxoid pseudotumors of fat. At present, the ...

Then, patients were randomized to either D-dimer testing or no D-dimer testing (controls). In the D-dimer group, patients with low clinical probabilities and negative D-dimer tests underwent no ...